Deucravacitinib Demonstrates Significantly Greater PASI Reductions in Plaque Psoriasis

Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

Related Keywords

Mark Lebwohl ,Arcutis Mark Lebwohl ,Icahn School Of Medicine At Mount Sinai ,Psoriasis Area ,Severity Index ,Clinical Dermatology ,Icahn School ,Physician Global Assessment ,